Humanize

The American medical establishment remains radically committed to the misnamed “gender-affirming care” model, refusing to even consider following the examples of the U.K., Sweden, Denmark, Finland, New Zealand, France, Norway, and others whose health ministries have hit the brakes hard on providing puberty blockers, hormones, and surgeries to gender dysphoric children.

Example: The current New England Journal of Medicine published a “Perspectives” screed attacking the Cass Review — widely respected for its thorough investigation of the lack of significant data supporting puberty blocking of gender dysphoric children. From “The Future of Gender Affirming Care“:

Our concern here is that the Review transgresses medical law, policy, and practice, which puts it at odds with all mainstream U.S. expert guidelines. The report deviates from pharmaceutical regulatory standards in the United Kingdom. And if it had been published in the United States, where it has been invoked frequently, it would have violated federal law because the authors failed to adhere to legal requirements protecting the integrity of the scientific process.